Radiant Logistics has acquired the Dallas operations of Whitacre Logistics, enhancing its intermodal and over-the-road brokerage services. The Dallas unit, serving industries like building materials and manufacturing, will continue under Jeff Vielhaber's leadership, who will also lead network development. This acquisition strengthens Radiant's bi-modal brokerage platform and expands its service offerings, including international forwarding and customs brokerage. The deal includes performance-based payments and aims to leverage Radiant's technology and expertise for growth across the U.S.
Radiant Logistics' acquisition of Whitacre Logistics' Dallas operations is presented here with context from the Industrials sector on Pluang. For readers following this sector, as of Oct 07, 2026 03:12 WIB, 56 of 93 priced US Industrials stocks rose while 34 fell. Notably, nVent Electric (NVT) traded at USD 173.81 with a 3.97% increase and 83% buy order activity, Modine Manufacturing Company (MOD) at USD 189.98 rose 3.87%, and Powell Industries (POWL) at USD 205.00 increased 3.62% with 100% buy orders, showing strong buying interest compared to their typical hold times ranging from 4 to 32 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
